Events
ASRS 2026: industry highlights and product innovations
Annual retina specialists meeting kicks off in Montreal with immersive, interactive experiences and technology showcases.
Events
ASRS 2026: your retina research rundown
Annual meeting of retina specialists kicks off in Montreal with updates on the latest clinical findings shaping the future of retina research.
Business
ASRS names new 2024-2025 president
Retinal specialist and vitreoretinal surgeon Reginald J. Sanders, MD, FASRS, has taken over leadership.
Products
ASRS reports safety concerns over Apellis' Syfovre
A reported six cases of retinal vasculitis have occurred in patients following the first intravitreal injection, the organization says.
Research
Adverum reports 5-year extension data on wet AMD gene therapy
At ASRS 2026, the OPTIC extension finds a single Ixo-vec injection led to a 87% cumulative reduction in annualized anti-VEGF injections.
Research
Real-world pegcetacoplan data shows VA benefits through 18 months
EHR and AI-based imaging analysis presented at ASRS demonstrates SYFOVRE advantages extending to GA patients with concomitant wet AMD.Research
New SYFOVRE data extend GA benefit to patients with concurrent wet AMD
SYFOVRE demonstrates reduced photoreceptor and RPE loss in GA patients and those with concomitant nAMD.
Research
Real-world data finds anti-VEGF use may not disrupt IZERVAY dosing patterns
IRIS Registry study demonstrates similarities in safety and dosing intervals among patients undergoing concomitant anti-VEGF and IZERVAY therapy.
Products
Eyes On Eyecare launches retina research-based app
Cited for Retina offers a “PubMed meets Instagram Stories” way for retina specialists to discover, digest, and react to new research shaping their practice.
Pipeline
4DMT releases 60-week phase 2 analysis on DME gene therapy
Reported at ASRS, data supports sustained vision gains and a 78% reduction in supplemental injections for 4D-150’s highest dose as company preps for phase 3 trial.
Pipeline
RegenxBio doses first patient in phase 2b/3 trial for DR
One-time gene therapy continues to move down the pipeline, with presentations on efficacy and safety data expected at ASRS.
Research
Genentech reports 5-year results on SUSVIMO for wet AMD
Presented at ASRS, new data reinforce the ranibizumab injection’s ability to provide an immediate and predictable durability as an alternative to regular eye injections.
Business
Apellis names retinal specialist as chief medical retina advisor
Former ASRS President Philip Ferrone, MD, will assume the role on March 18.
Research
Pediatric ROP associated with higher strabismus risk
Treatment-requiring retinopathy of prematurity carried a 34.78% 5-year cumulative incidence of strabismus, with esodeviations leading the pattern.
Business
National Academy of Opticianry and United Opticians Association kick-start potential merger
Announcement follows both organizations’ vote to authorize a formal process last week; next phase involves review by a joint steering committee.
Pipeline
FDA agrees to special protocol assessment for Oculis’s phase 3 ON trial
Agreement on the PIONEER-1 study offers regulatory alignment on privosegtor’s registration path as a potential neuroprotective candidate.
Events
ASCRS 2026 highlights key trends in surgical ecosystem
Annual meeting of cataract and refractive surgeons kicks off in the nation’s capital with focus on developments in surgical devices and IOLs.
Products
CMS assigns Glaukos’ Epioxa a permanent J-code
Corneal CXL therapy was approved in October 2025 as the first topical drug not requiring removal of the corneal epithelium for keratoconus treatment.
Pipeline
FDA grants Fast Track designation for Drug Farm's ROSAH syndrome asset
Status enables expedited regulatory review process for DF-003, designed to target the genetic root cause of this rare genetic disease.
Pipeline